Melius Pharma

Melius Pharma is a private, clinical-stage biotech based in Stockholm, Sweden, leveraging a low-risk development model. The company's core asset is ME-015 (suplatast tosilate), a drug with over 25 years of real-world safety data in Japan, now in Phase 2 for chronic cough in IPF. Melius's strategy involves sourcing late-stage assets with proven safety profiles and developing them in high-value, niche indications to reduce clinical risk and enhance partnering appeal. The company is backed by seasoned Swedish life science investors and is targeting topline Phase 2 readouts in 2025.

Strategic development model focused on repurposing late-stage clinical assets with extensive real-world safety data from other regions (e.g., Japan) for new, high-value indications to de-risk clinical development.

The competitive landscape for IPF itself includes approved anti-fibrotics (pirfenidone, nintedanib) which do not specifically treat cough. The niche of IPF-associated chronic cough has few direct competitors, but the broader refractory chronic cough space is active with several novel mechanisms (e.g., P2X3 antagonists) in development, which could eventually expand into IPF.